Executive Interview Series with Chief Scientific Officer Dr. Tracy Mynott
CHIEF SCIENTIFIC OFFICER
Dr Tracey Mynott
Tracey is one of the inventors of the Detach(TM) technology, being involved with its development in the 1990s, and more recently with the development of the new formulation.
Tracey has a PhD in the pathogenesis of enteric infections with a particular focus on the Detach(TM) concept and enterotoxigenic E. coli infections. She has conducted post-doctoral studies at The Centre for Vaccine Development at the University of Maryland in USA, the Division of Gastroenterology within The Royal College of Physicians and Surgeons at Columbia University in New York, the Digestive Diseases Research Centre at the Medical College of St Bartholomew's Hospital in London and in the Department of Biochemistry, Imperial College in London.
Tracey is the former Head of Business Development at the Queensland Institute of Medical Research, one of Australia's most prestigious research organisations. She has also held senior management positions in public and private Australian and UK biotechnology companies, where she has successfully discovered and patented several technologies, devised and directed drug development and clinical programs, developed and implemented business strategies, including licensing, acquisitions, capital raising and marketing.
What is Detach(TM)?
Detach(TM) is a modified release formulation of BromelainRx, a natural extract from pineapple stems.
It is formulated with various ingredients to allow oral administration and its efficient delivery to the small intestine.
Detach(TM) has already been proven to be effective in treating diarrhoea in pigs, known as scour, and may also be used in other farm livestock such as calves and chickens.
Anti-microbial resistance, or antibiotic resistance, is a serious global health problem, and an urgent solution is required to reduce the use of antibiotics in stockfeed.
It is well understood that the more that disease-causing bacteria become resistant to antibiotics, the harder it will be to treat diseases.
Anatara's Detach(TM) meets an urgent and unmet need for effective alternatives to antibiotics.
As consumers become more concerned about their food and its impact on their health, alternatives to antibiotics can provide the livestock industry with a competitive advantage in its marketing to consumers.
The active ingredient in Detach(TM), BromelainRx, is already approved for human use, and has an extensive safety record.
About Scour and the impact of Detach(TM) on scour
Scour affects hundreds of millions of pigs and other farm animals around the world, impacting on their growth, and adversely impacting farming economics, through reduced meat production yields.
In clinical trials in several thousand piglets on commercial farms, a single, oral dose of Detach(TM) reduced scour and scour-related death, reduced the requirement for antibiotics, and increased weight gains without the need for changes to on-farm management practices.
For more information about Detach(TM) and its mode of action, please visit the Technology section of this website.
Detach(TM) in the field
Detach(TM) has demonstrated efficacy in clinical trials involving more than 6,000 piglets on multiple Australian commercial pig farms, where it reduced scour and scour-related death, improved weight gains and reduced the requirement for antibiotic use. The results from these trials were analysed by the CSIRO using an AusPig computer program and were published in this article, in Milne's Pork Journal, a leading world pig industry journal. The analysis indicated that Detach(TM) provided an economic benefit of 45% improvement in net revenue per pig or $5.26 per pig.
In 2012, Anatara completed successful field studies in Europe on commercial pig farms and demonstrated that a new formulation of Detach(TM) is as effective as it was in 1991. In one recent trial Detach(TM) improved feed conversion ratios by up to 33%, when compared with piglets treated with colistin (an antibiotic) added to feed.
To view the video, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.
Commonwealth Bank of Australia
Anatara Lifesciences Ltd